Hui Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Lu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Shiyu Li
Department of Immunology & Institute of Geriatric Immunology School of Medicine Jinan University Guangzhou China
2 shared publications - Zhenning Dai
Department of Stomatology, Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, 510095, China
2 shared publications - Baoyu Sun
Institute of translational medicine, Shanghai University, Shanghai, 200444, China
1 shared publication - Bing Zhang
Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Department of Cardiovascular Surgery, Shanghai Chest Hospital, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication - Ding Li1 shared publication
- Guobing Chen
Department of Microbiology and Immunology, School of Medicine; Institute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by AccScience Publishing in Organoid Research
- Vol. 2 (3) , 026140021
Bone organoid–derived extracellular vesicles promote angiogenesis and osteogenesis in vitro
Bone organoids (BOs) demonstrate excellent therapeutic effects in bone defect transplantation, but their high cultivation difficulty and cost limit widespread adoption, prompting us to focus on their derivatives. Whether BO-derived extracellular vesicles (BOEVs) can promote bone regeneration and whether they offer greater advantages than stem cell-derived extracellular vesicles (EVs) remains unclear. In this study, we isolated rat bone marrow mesenchymal stem cells (BMSCs) and induced them into BOs. As culture duration increased, BO size gradually enlarged to 203.71 ± 45.30 μm, but the number of spheroids progressively decreased. Messenger RNA (mRNA) sequencing revealed that after seven days of culture, BOs exhibited hypoxic alterations, leading to increased expression of cytokines, including hypoxia-inducible factor-1α (HIF-1α). Subsequently, BOEVs were isolated from BO culture medium at corresponding time points. Both BOEVs cultured for seven days (BOEV-7d) and 14 days (BOEV-14d) were enriched with bone morphogenetic protein 2 (BMP-2), transforming growth factor beta 1 (TGF-β1), HIF-1α, and vascular endothelial growth factor (VEGF). Co-culturing BOEVs with human umbilical vein endothelial cells and hFOB1.19 cells revealed that BOEV-7d significantly promoted tube length and branching while upregulating VEGF and CCN2 mRNA, demonstrating superior effects compared to BOEV-1d and BOEV-14d. Concurrently, BOEV-7d enhanced alizarin red S staining levels in hFOB1.19 cells, while the expression of osteogenesis-related genes Runx2, Col1a1, and Ocn was positively correlated with culture duration. Notably, BOEVs demonstrated significantly greater osteogenic and angiogenic effects than BMSC-derived EVs in 2D culture. This study demonstrates, in vitro, that BOEVs play dual roles in bone and vascular regeneration and have the potential to modulate the vascularization–osteogenesis pathway in bone defects. It offers insights into bone defect treatment and inspires research on organoid-derived EVs.
- 18 September 2026
- Published by AccScience Publishing in Organoid Research
- Vol. 2 (3) , 026140021
Open AccessBone organoid–derived extracellular vesicles promote angiogenesis and osteogenesis in vitro
Bone organoids (BOs) demonstrate excellent therapeutic effects in bone defect transplantation, but their high cultivation difficulty and cost limit widespread adoption, prompting us to focus on their derivatives. Whether BO-derived extracellular vesicles (BOEVs) can promote bone regeneration and whether they offer greater advantages than stem cell-derived extracellular vesicles (EVs) remains unclear. In this study, we isolated rat bone marrow mesenchymal stem cells (BMSCs) and induced them into BOs. As culture duration increased, BO size gradually enlarged to 203.71 ± 45.30 μm, but the number of spheroids progressively decreased. Messenger RNA (mRNA) sequencing revealed that after seven days of culture, BOs exhibited hypoxic alterations, leading to increased expression of cytokines, including hypoxia-inducible factor-1α (HIF-1α). Subsequently, BOEVs were isolated from BO culture medium at corresponding time points. Both BOEVs cultured for seven days (BOEV-7d) and 14 days (BOEV-14d) were enriched with bone morphogenetic protein 2 (BMP-2), transforming growth factor beta 1 (TGF-β1), HIF-1α, and vascular endothelial growth factor (VEGF). Co-culturing BOEVs with human umbilical vein endothelial cells and hFOB1.19 cells revealed that BOEV-7d significantly promoted tube length and branching while upregulating VEGF and CCN2 mRNA, demonstrating superior effects compared to BOEV-1d and BOEV-14d. Concurrently, BOEV-7d enhanced alizarin red S staining levels in hFOB1.19 cells, while the expression of osteogenesis-related genes Runx2, Col1a1, and Ocn was positively correlated with culture duration. Notably, BOEVs demonstrated significantly greater osteogenic and angiogenic effects than BMSC-derived EVs in 2D culture. This study demonstrates, in vitro, that BOEVs play dual roles in bone and vascular regeneration and have the potential to modulate the vascularization–osteogenesis pathway in bone defects. It offers insights into bone defect treatment and inspires research on organoid-derived EVs.
- Top Cited PapersOpen Access
- 1 April 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 58, 252-273
Extracellular vesicles from IPFP-MSCs trigger osteoarthritis by transferring mtDNA
Infrapatellar fat pad mesenchymal stem cells (IPFP-MSCs) extracellular vesicles (EVs) are found to be capable of accelerating Osteoarthritis (OA) progression. However, which pathways and which pathogenic EVs subgroups are involved are not defined. In our study we found that there were a higher percentage of TOMM20+ EV's within the total synovial fluid EV's from OA patients than from trauma patients as well as increased mtDNA content. This implicates the mitochondria derived EV sub-group - mitochondria derived vesicles (MDVs) as a potential driver in OA. We found with the single-cell data that MDVs may be secreted from IPFP-MSCs with VPS35. Furthermore, these cells were harvested from the body of the OA patient. IPFP-MSC derived MDVs can deliver exogenous mtDNA to chondrocytes by fusing directly, thus inhibiting chondrocyte matrix synthesis, inducing mitochondrial dysfunction, and activating pro-inflammatory signaling cascades in chondrocytes. Protein microarrays showed that MDVs delivered exogenous mtDNA to chondrocytes, which then activated the cGAS-STING pathway and downstream inflammatory mediators (TBK1, NF-κB, TNF-α). Intra-articular MDV injection worsened cartilage degradation and synovitis in OA rats but STING inhibition alleviated them. This study showed that IPFP-MSC-derived MDVs are essential for OA pathogenesis via mtDNA transfer and cGAS-STING pathway activation. These results show how the mitochondria and immune system talk to each other in the joints causing pain and destroying the cartilage, MDVs are new things that can tell us if someone has this disease and help doctors fix it. Pharmacological blockade of the cGAS-STING axis has shown therapeutic potential, providing a dual approach to mitigate mitochondrial stress and innate immune hyperactivation in OA.
- 1 April 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 58, 252-273
Top Cited PapersOpen AccessExtracellular vesicles from IPFP-MSCs trigger osteoarthritis by transferring mtDNA
Infrapatellar fat pad mesenchymal stem cells (IPFP-MSCs) extracellular vesicles (EVs) are found to be capable of accelerating Osteoarthritis (OA) progression. However, which pathways and which pathogenic EVs subgroups are involved are not defined. In our study we found that there were a higher percentage of TOMM20+ EV's within the total synovial fluid EV's from OA patients than from trauma patients as well as increased mtDNA content. This implicates the mitochondria derived EV sub-group - mitochondria derived vesicles (MDVs) as a potential driver in OA. We found with the single-cell data that MDVs may be secreted from IPFP-MSCs with VPS35. Furthermore, these cells were harvested from the body of the OA patient. IPFP-MSC derived MDVs can deliver exogenous mtDNA to chondrocytes by fusing directly, thus inhibiting chondrocyte matrix synthesis, inducing mitochondrial dysfunction, and activating pro-inflammatory signaling cascades in chondrocytes. Protein microarrays showed that MDVs delivered exogenous mtDNA to chondrocytes, which then activated the cGAS-STING pathway and downstream inflammatory mediators (TBK1, NF-κB, TNF-α). Intra-articular MDV injection worsened cartilage degradation and synovitis in OA rats but STING inhibition alleviated them. This study showed that IPFP-MSC-derived MDVs are essential for OA pathogenesis via mtDNA transfer and cGAS-STING pathway activation. These results show how the mitochondria and immune system talk to each other in the joints causing pain and destroying the cartilage, MDVs are new things that can tell us if someone has this disease and help doctors fix it. Pharmacological blockade of the cGAS-STING axis has shown therapeutic potential, providing a dual approach to mitigate mitochondrial stress and innate immune hyperactivation in OA.